Skip to main content

Table 2 Summary of response to cannabis derivatives for individuals with CDD from two COEs

From: Current neurologic treatment and emerging therapies in CDKL5 deficiency disorder

Treatment

# individuals

# individuals with known response

2-week response (n, (% of those taking with known response))

3-month response (n, (% of those taking with known response))

Worsening seizures (n, (% of those taking with known response))

No change (n, (% of those taking with known response))

Cannabidiol (Epidiolex)

19

14 (74%)

4 (29%)

3 (21%)

4 (29%)

6 (43%)

Non-FDA-approved cannabis derivative

18

4 (19%)

2 (50%)

2 (50%)

1 (25%)

2 (50%)